Jounce Therapeutics, Inc.
JNCE · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.13 | 0.12 | 0.00 |
| FCF Yield | 102.88% | -26.27% | -15.17% | -9.49% |
| EV / EBITDA | -1.64 | -1.77 | -2.74 | -8.22 |
| Quality | ||||
| ROIC | 26.00% | -22.39% | -19.88% | -18.57% |
| Gross Margin | 100.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.16 | 1.02 | 0.70 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.57% | 29,865.52% | -99.39% | -42.99% |
| Free Cash Flow Growth | 285.69% | -33.79% | 28.61% | -17.46% |
| Safety | ||||
| Net Debt / EBITDA | -2.77 | 2.14 | 1.99 | 1.29 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |